Khor L-Y, DeSilvio M, Li R, McDonnell TJ, Hammond ME, Sause W, Pilepich M, Okunieff P, Sandler H, Pollack A. Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in radiation therapy oncology group protocol 86-10. Int. J. Radiat. Oncol. Biol. Phys.. 2006, In-Press.
Pollack A, Hanlon AL, Horwitz EM, Steven J. Feigenberg SJ, Konski AA, Movsas B, Greenberg RE, Uzzo RG, Ma C-MC, McNeeley SW, Buyyounouski MK, Price RA. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int. J. Radiat. Oncol. Biol. Phys. 64:518-526, 2006
Abdel-Wahab M, Berkey BA, Krishan A, O’Brien T, Hammond E, Roach M, Lawton C, Pilepich, M, Markoe A, Pollack A. Influence of number of CAG repeats on local control in the RTOG 86-10 protocol. Am. J. Clin. Oncol. 29:14-20, 2006
Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph-node involvement. Int. J. Radiat. Oncol. Biol. Phys. 61:695-701, 2005
Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation? Int. J. Radiat. Oncol. Biol. Phys. 61:1003-1010, 2005
Watkins Bruner D, Linton S, Konski A, Uzzo RG, Greenberg RE, Pollack A, Gordon R, Cescon TP, Daly M, Young W, Goplerud J, Higman Tofani S, Engstrom P. Successful strategies for African American recruitment to prostate cancer research. Int. J. Cancer Prev. 1:295-306, 2005
Buyyounouski MK, Hanlon AL, Horwitz EM, Uzzo RG, Pollack A. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. Int. J. Radiat. Oncol. Biol. Phys. 61:1291-1298, 2005
Chakravarti A, Winter K, Wu C, Kaufman D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, Pollack A, Sandler H, Shipley W. Expression of the Epidermal Growth Factor Receptor (EGFR) and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the Radiation Therapy Oncology Group (RTOG). Int. J. Radiat. Oncol. Biol. Phys. 62:309-317, 2005.
Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D, Pollack A. Long-term androgen deprivation increases grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 62:397-405, 2005
Andrews SF, Horwitz EM, Feigenberg SJ, Eisenberg DF, Hanlon AL, Uzzo RG, Pollack A. Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma? Cancer 104:299-304, 2005
Khor LY, Desilvio M, Al-Saleem T, Hammond ME, Grignon DJ, Sause W, Pilepich M, Okunieff P, Sandler H, Pollack A. MDM2 as a predictor of prostate carcinoma outcome. An analysis of RTOG protocol 86-10. Cancer 104:962-967, 2005
Nguyen KH, Hachem P, Khor L-Y, Salem N, Hunt K, Calkins P, Pollack A. Adenoviral-E2F-1 radiosensitizes p53 and p53 human prostate cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 63:238-246, 2005
Mu Z, Hachem P, Pollack A. Antisense Bcl-2 sensitizes prostate cancer cells to radiation. Prostate 65:331-340, 2005
Buyyounouski MK, Hanlon AL, Eisenberg DF, Horwitz EM, Feigenberg SJ, Uzzo RG, Pollack A. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. Int. J Radiat. Oncol. Biol. Phys. 63:1455-1462, 2005
Paskalev K, Feigenberg S, Jacob R, McNeeley S, Horwitz E, Price R, Ma C, Pollack A. Target localization for post-prostatectomy patients using CT and ultrasound image guidance. J.Appl. Clin. Med. Phys. 6:40-49, 2005
Hanlon AL, Horwitz EM, Hanks GE, Pollack A. Short-term androgen deprivation and PSA doubling time: Their association and relationship to disease progression after radiation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 58:43-52, 2004.
Watkins Bruner D, Hanlon A, Mazzoni S, Raysor S, Konski A, Hanks G, Pollack A. Predictors of preferences and utilities in men treated with 3D-CRT for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 58:34-42, 2004.
Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. The relationship of increasing radiotherapy dose to reduced distant metastasis and mortality in men with prostate cancer. Cancer 100:538-543, 2004.
Mu Z, Hachem P, Agrawal S, Pollack A. Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination. Int. J. Radiat. Oncol. Biol. Phys. 58:336-343, 2004.
Buyyounouski MK, Horwitz EM, Price RA, Hanlon AL, Uzzo RG, Pollack A. Intensity-modulated radiotherapy with MRI Simulation to reduce doses received by erectile tissue during prostate cancer treatment. Int. J. Radiat. Oncol. Biol. Phys. 58:743-749, 2004.
Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG, Hanks GE. Prostate cancer radiotherapy dose response: An update of the Fox Chase experience. J. Urol. 171:1132-1136, 2004.
Paskalev K, Ma C-M, Jacob R, Price R, McNeeley S, Wang L, Movsas B, Pollack A. Daily target localization for prostate patients based on 3D image correlation. Physics Med. Biol. 49: 931-939, 2004.
Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A. A comparison of the single and double factor high risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 59: 380-385, 2004.
Andrews SF, Anderson PR, Eisenberg BL, Hanlon AL, Pollack A. Soft tissue sarcomas treated with postoperative external beam radiotherapy with and without low-dose-rate brachytherapy. Int. J. Radiation Oncology Biol Phys. 59:475-480, 2004.
Pollack A, DeSilvio M, Khor L-Y, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach III M, Shipley WU, Hanks GE, Sandler HM. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: An analysis of RTOG 92-02. J. Clin. Oncol. 22:2133-2140, 2004.
Mu Z, Hachem P, Agrawal S, Pollack A. Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation. Prostate 60: 187-196, 2004.
Li JS, Freedman GM, Price R, Wang L, Anderson P, Chen L, Xiong W, Yang J, Pollack A, Ma C-M. Clinical Implementation of intensity-modulated tangential beam irradiation for breast cancer. Med. Phys. 31:1023-1031, 2004.
Li R, Heydon K, Hammond ME, Grignon D, Roach M, Wolkov H, Sandler HM, Shipley WU, Pollack A. Ki-67 Staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: An analysis of patients in RTOG Protocol 8610. Clin. Cancer Res. 4118-4124, 2004.
Buyyounouski MK, Horwitz EM, Uzzo RG, Price RA, McNeeley SW, Azizi D, Hanlon AL, Milestone BN, Pollack A. Radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 59:1383-1391, 2004.
Uzzo RG, Brown JG, Horwitz EM, Hanlon A, Mazzoni S, Konski A, Greenberg RE, Pollack A, Kolenko V, Watkins-Bruner D. Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer. BTU Int. 93:955-960, 2004.
Chen L, Price RA, Nguyen T-B, Wang L, Li JS, Qin L, Ding M, Palacio E, Ma C-M, Pollack A. Dosimetric evaluation of MRI-based treatment planning for prostate cancer. Phys. Med. Biol. 49:5157-5170, 2004.
Pollack A., Price R, Dong L, Feigenberg S, Horwitz E. Intact prostate cancer: Overview In: AJ Mundt and JC Roeske (eds.), Intensity Modulated Radiation Therapy: A Clinical Perspective. BC Decker, Inc, ON, Canada 2005, pp 436-448
Price RA, Horwitz EM, Feigenberg SJ, Pollack A. Intact prostate cancer: Case Study. In: AJ Mundt and JC Roeske (eds.), Intensity Modulated Radiation Therapy: A Clinical Perspective. BC Decker, Inc, ON, Canada 2005, pp 459-463
Feigenberg SJ, Pollack A, Price RA, McNeeley SW, Horwitz EM. Prostate. In: KS Clifford Chao, S Apisarnthanarax, G Ozyigit (eds.), Practical Essentials of Intensity Modulated Radiation Therapy, Second Edition. Lippincott Williams & Wilkins, Philadelphia, PA 2004.
Loehrer PJ, Ahlering TE, Pollack A. Testicular cancer. In: R Pazdur, LR Coia, WJ Hoskins, LD Wagman (eds.), Cancer Management: A Multidisciplinary Approach, Ninth Edition. The Oncology Publishing Group, Lawrence, KS, 2005, pp 407-427.
Pollack, A. Adjuvant and salvage radiotherapy post-prostatectomy. In: NJ Vogelzang, PT Scardino, WU Shipley, FMJ Debruyne, WM Linehan. (eds.), Comprehensive Textbook of Genitourinary Oncology Third Edition. Lippincott Williams & Wilkins, Baltimore, MD 2005, pp295-306
Buyyounouski MK, Horwitz EM, Price RA, Feigenberg SJ, Pollack A. Prostate IMRT . In: Image-Guided IMRT. T Bortfeld, R Schmidt-Ullrich, W de Neve (eds.), Springer-Verlag Heidelberg, Germany, 2006, pp 391-410.
Buyyounouski MK and Pollack A. External Beam Radiotherapy for Prostate
Cancer. In Atlas of the Prostate; 3rd Ed., PT. Scardino, KM Slawin (eds.), Current Medicine LLC, Philadelphia, USA, 2006, pp 193-213
Horwitz EM, Feigenberg SJ, Pollack A. Initial management of high risk early stage prostate cancer: Radiation. In: Kirby RS, Partin AW, Feneley M, and Parsons JK, eds. Prostate Cancer – Principles and Practice. Boca Raton: Taylor & Francis, 2006, pp 855-863
Buyyounouski, M.K., Horwitz, E.M., Hanlon, A.L., Uzzo, R.G., Hanks, G.E., Pollack, A. Positive prostate biopsy laterality and implications for staging. Urology 62:298-303, 2003.
Chandra, A., Dong, L., Huang, E., Kuban, D.A., O'Neill, L., Rosen, I., Pollack, A. Experience of ultrasound-based daily prostate localization. Int. J. Radiat. Oncol. Biol. Phys. 56:436-447, 2003.
Chism, D.B., Hanlon, A.L., Troncoso, P., Al-Saleem, T., Horwitz, E.M., Pollack, A. The Gleason score shift: score four and seven years ago. Int. J. Radiat. Oncol. Biol. Phys. 56:1241-1247, 2003.
Chism, D.B., Horwitz, E.M., Hanlon, A.L., Pinover, W.H., Mitra, R.J., Hanks, G.E. Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement. Int. J. Radiat. Oncol. Biol. Phys. 55:71-77; 2003.
D'Souza, W.D., Lee, H.K., Palmer, M.B., Smith, L.G., Pollack, A. Is intraoperative nomogram-based overplanning of prostate implants necessary? Int. J. Radiat. Oncol. Biol. Phys. 56:462-467, 2003.
Diefenbach, M.A., Hamrick, N., Uzzo, R., Pollack, A., Horwitz, E., Greenberg, R., Engstrom, P.F. Clinical, demographic and psychosocial correlates of complementary and alternative medicine use by men diagnosed with earlystage prostate cancer. J. Urol. 170:166-169, 2003.
Feigenberg, S.J., Amdur, R.J., Morris, C.G., Mendenhall, W.M., Marcus, R.B., Friedman, W.A. Oligodendrogliomas: Does deferring treatment compromise outcome? Am. J. Clin. Oncol. 26:E60-66; 2003.
Feigenberg, S.J., Mendenhall, N.P., Benda, R.K., Morris, C.G. Postmastectomy radiotherapy: Patterns of recurrence and long-term disease control using electrons. Int. J. Radiat. Oncol. Biol. Phys. 56:716-725, 2003.
Feigenberg, S.J., Wolk, K.L., Yang, C.H., Morris, C.G., Zlotecki, R.A. Celecoxib to decrease urinary retention associated with prostate brachytherapy. Brachytherapy 2:103-107, 2003.
Freedman, G.M., Anderson, P.R., Goldstein, L.J., Hanlon, A.L., Cianfrocca, M.E., Millenson, M.M., Torosian, M.H., Boraas, M.C., Nicolaou, N., Patchefsky, A.S., Evers, K. Routine mammography is associated with earlier stage disease and greater eligibility for breast conservation in women aged 40 and older with breast cancer. Cancer 98:918-925, 2003.
Hammond, E., Berkey, B.A., Fu, K.K., Trotti, A., Meredith, R., Jones, C.U., Byhardt, R., Horwitz, E.M., Ang, K.K. P105 as a prognostic indicator in patients irradiated for locally advanced head and neck cancer: A clinical/ laboratory correlative analysis of RTOG 9003. Int. J. Radiat. Oncol. Biol. Phys. 57:683-692, 2003.
Hanks, G.E., Pajak, T.F., Porter, A., Grignon, D., Brereton, H., Venkatesan, V., Horwitz, E.M., Lawton, C., Rosenthal, S.A., Sandler, H.M., Shipley, W.U. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group 92-02. J. Clin. Oncol. 21(21):3972-3978, 2003.
Horwitz, E.M., Uzzo, R., Hanlon, A.L., Greenberg, R., Hanks, G.E., Pollack, A. Modifying the ASTRO definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3D conformal radiation therapy alone. J. Urol. 169:2153-2159, 2003.
Horwitz, E.M., Mitra, M.K., Uzzo, R.G., Da, I.K., Pinover, W.H., Hanlon, A.L., McNeeley, S.W., Hanks, G.E. Impact of target volume coverage with RTOG 98-05 guidelines for transrectal ultrasound guided permanent I-125 prostate implants. Radiother. Oncol. 66:173-179, 2003.
Horwitz, E.M. Conformal radiotherapy with dose escalation appears safe and effective in localized prostate cancer. Cancer Treat. Rev. 29:219-221, 2003.
Kaminski, J.M.L., Hanlon, A.L., Joon, D.L., Meistrich, M., Hachem, P., Pollack, A. Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth. Int. J. Radiat. Oncol. Biol. Phys. 57:24-28, 2003.
Kuban, D., Pollack, A., Huang, E., Levy, L., Dong, L., Starkschall, G., Rosen, I. Hazards of dose escalation in prostate cancer radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 57:1260-1268, 2003.
Monroe, A., Feigenberg, S.J., Mendenhall, N.P. Angiosarcomas after breast conservation. Cancer 97:1832-1840, 2003.
Movsas, B. Quality of life in oncology trials: A clinical guide. Semin. Radiat. Oncol. 13:235-247, 2003.
Nahum, A.E., Movsas, B., Horwitz, E.M., Stobbe, C.C., Chapman, J.D. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the / ratio. Int. J. Radiat. Oncol. Biol. Phys. 57:391-401, 2003.
Nguyen, K.H., Horwitz, E.M., Hanlon, A.L., Uzzo, R.G., Pollack, A. Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. 57:377-383, 2003.
Pinover, W.H., Horwitz, E.M., Hanlon, A.L., Uzzo, R.G., Hanks, G.E. Validation of a treatment policy for PS failures following 3-D conformal prostate radiation therapy. Cancer 97:1127-1133; 2003.
Pollack, A., Hanlon, A.L., Movsas, B., Hanks, G.E., Uzzo, R., Horwitz, E.M. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 57:19-23, 2003.
Pollack, A., Horwitz, E.M., Movsas, B. Treatment of prostate cancer with regional lymph node (N1) metastasis. Semin. Radiat. Oncol. 13:121-129, 2003.
Pollack, A., Horwitz, E.M., Movsas, B., Hanlon, A.L. Mindless or mindful? Radiation Oncologists' perspectives on the evolution of prostate cancer treatment. Urol. Clin. N. Am. 30:337-350, 2003.
Scott, W.J., Howington, J., Movsas, B. Treatment of stage II non-small cell lung cancer. Chest 123:188S-201S, 2003.
Taylor, N., Kelly, J.F., Kuban, D.A., Babaian, R.J., Pisters, L.L., Pollack, A. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 56:755-763, 2003.
Uzzo, R.G., Pinover, W.H., Horwitz, E.H., Parlanti, A., Mazzoni, S., Raysor, S., Mirchandani, I., Greenberg, R.E., Pollack, A., Hanks, G.E., Watkins-Bruner, D. Free prostate specific antigen improves prostate cancer detection in a high risk population of men with a normal total PSA and digital rectal examination. Urology 61:754-759, 2003.
Diefenbach, M.A., Dorsey, J., Uzzo, R.G., Hanks, G.E., Greenberg, R.E., Horwitz, E.M., Newton, F., Engstrom, P.F. Decision-making strategies for patients with localized prostate cancer. Semin. Urol. Oncol. 20:55-62, 2002.
Freedman, G., Hanlon, A., Fowble, B., Anderson, P., Nicolaou, N. Recursive partitioning identifies patients at high and low risk for ipsilateral tumor recurrence after breast-conserving surgery and radiation. J. Clin. Oncol. 20:4015-4021, 2002.
Hanks, G.E., Hanlon, A.L., Epstein, B., Horwitz, E.M. Dose response in prostate cancer with 8-12 year follow-up. Int. J. Radiat. Oncol. Biol. Phys. 54:427-435, 2002.
Hanlon, A.L., Diratzouian, H., Hanks, G.E. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 53:297-303, 2002.
Huang, E.H., Pollack, A., Levy, L., Starkschall, G., Dong, L., Rosen, I., Kuban, D.A. Late rectal toxicity: Dosevolume effects of conformal radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 54:1314-1321, 2002.
Kaminski, J.M., Hanlon, A.L., Horwitz, E.M., Pinover, W.H., Mitra, R.K., Hanks, G.E. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control. Int. J. Radiat. Oncol. Biol. Phys. 52:888-892, 2002.
Komaki, R., Seiferheld, W., Ettinger, D., Lee, J.S., Movsas, B., Sause, W. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small cell lung cancer: Long-term follow-up of RTOG 92-04. Int. J. Radiat. Oncol. Biol. Phys. 53:548-557, 2002.
Kramer, N.M., Hanlon, A.L., Horwitz, E.M., Pinover, W.H., Hanks, G.E. Biochemical failure rates in prostate cancer patients predicted to have biochemically insignificant tumors treated with three-dimensional conformal radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 53:277-281, 2002.
Mah, D., Steckner, M., Hanlon, A., Freedman, G., Milestone, B., Mitra, R., Shukla, H., Movsas, B., Horwitz, E., V?is?nen, P.P., Hanks, G.E. MRI simulation: Effect of gradient distortions on three-dimensional prostate cancer plans. Int. J. Radiat. Oncol. Biol. Phys. 53:757-765, 2002.
Mah, D., Freedman, G., Milestone, B., Hanlon, A., Palacio, E., Richardson, T., Movsas, B., Mitra, R., Horwitz, E., Hanks, G.E. Measurement of intrafractional prostate motion using magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys. 54:568-575, 2002.
Movsas, B., Chapman, J.D., Hanlon, A.L., Horwitz, E.M., Greenberg, R.E., Stobbe, C., Hanks, G.E., Pollack, A. Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 60:634-639, 2002.
Pollack, A., Zagars, G.K., Starkschall, G., et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 53:1097-1105, 2002.
Pollack, A., Zagars, G.K., Antolak, J.A., Kuban, D.A., Rosen, I.I. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: Analysis of a prostate cancer randomized radiation dose escalation trial. Int. J. Radiat. Oncol. Biol. Phys. 54:677-85, 2002.
Pollack, A., Kuban, D.A., Zagars, G.K. Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer. Urology 60:22-31, 2002.
Fowble, B., Hanlon, A., Freedman, G., Nicolaou, N., Anderson, P. Second cancers after conservative surgery and radiation for stage I-II breast cancer: Identifying a subset of women at increased risk. Int. J. Radiat. Oncol. Biol. Phys. 51:679-690, 2001.
Hanks, G.E., Hanlon, A.L., Horwitz, E.M. Evidence for cure of 'young' men with prostate cancer. Oncology 15:563-567, 2001.
Hanlon, A.L., Bruner, D.W., Peter, R., Hanks, G.E. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: Comparing late bowel and bladder quality of life symptoms to that of the normal population. Int. J. Radiat. Oncol. Biol. Phys. 49:51-59, 2001.
Hanlon, A.L., Pinover, W.H., Horwitz, E.M., Hanks, G.E. Patterns and fate of PSA bouncing following 3D-CRT. Int. J. Radiat. Oncol. Biol. Phys. 50:845-849, 2001.
Horwitz, E.M., Hanlon, A.L., Pinover, W.H., Anderson, P.R., Hanks, G.E. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer 92:1281-1287, 2001.
Horwitz, E.M., Winter, K., Hanks, G.E., Lawton, C.A., Russell, A.H., Machtay, M. Subset analysis of RTOG 85- 31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 49:947-956, 2001.
Mah, D., Freedman, G., Movsas, B., Hanlon, A., Mitra, R., Horwitz, E., Pinover, W., Iyer, R., Hanks, G.E. To move or not to move: measurements of prostate motion by urethrography using MRI. Int. J. Radiat. Oncol. Biol. Phys. 50:947-951, 2001.
Movsas, B., Chapman, J.D., Hanlon, A.L., Horwitz, E.M., Pinover, W.H., Greenberg, R.E., Stobbe, C., Hanks, G.E. Hypoxia in human prostate carcinoma: an Eppendorf PO2 study. Am. J. Clin. Oncol. 24:458-461, 2001.
Movsas, B., Hudes, R.S., Schol, J., Nicolaou, N., Millenson, M., Rosvold, E., Litwin, S., Keenan, E., Curran, W.J., Jr., Langer, C.J. Induction and concurrent paclitaxel-carboplatin every 3 weeks with thoracic radiotherapy in locally advanced non-small cell lung cancer. Lung Cancer 3:125-132, 2001.
Movsas, B., Li, B.S.Y., Babb, J.S., Fowble, B., Nicolaou, N., Martin, P., Gonen, O. Quantifying radiation-therapy induced brain injury with whole brain magnetic resonance spectroscopy. Radiology 221:327-331, 2001.
Pingpank, J.F., Hoffman, J.P., Ross, E.A., Cooper, H.S., Meropol, N.J., Freedman, G., Pinover, W.H., LeVoyer, T.E., Sasson, A.R., Eisenberg, B.L. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J. Gastrointestinal Surg. 5:121-130, 2001.
Pollack, A., Salem, N., Ashoori, F., Hachem, P., Sangha, M., von Eschenbach, A.C., Meistrich, M.L. Lack of prostate cancer radiosensitization by androgen deprivation. Int. J. Radiat. Oncol. Biol. Phys. 51:1002-1007, 2001.
Sasson, A.R., Fowble, B., Hanlon, A.L., Torosian, M.H., Freedman, G., Boraas, M., Sigurdson, E.R., Hoffman, J.P., Eisenberg, B.L., Patchefsky, A. Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation. Cancer 91:1862-1869, 2001.
Sasson, A.R., Hoffman, J.P., Ross, E., Meropol, N.J., Szarka, C.E., Freedman, G., Pinover, W., Pingpank, J.F., Eisenberg, B.L. Trimodality therapy for advanced gallbladder cancer. The Am. Surg. 67:277-284, 2001.